EUVIMEDEUVIMED entdecken
Crossref

Potential Efficacy of Proteasome Inhibitor, Delanzomib, for the Treatment of Renal Fibrosis

Ayano Sawa-Aihara, Katsuji Hattori, Goshi Nagao, Yoshihisa Yamada, Tatsuhiro Ishida

Biological and Pharmaceutical Bulletin · 2023

DOI: 10.1248/bpb.b22-00713 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biological and Pharmaceutical Bulletin, 2023. Verfasst von Ayano Sawa-Aihara und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacokinetics and Biopharmaceutics, Institute of Biomedical Sciences, Tokushima University. Hauptthemen laut MEDLINE: Proteasome Inhibitors, Kidney Diseases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 42 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proteasome InhibitorsKidney DiseasesMiceAnimalsHumansRenal DialysisKidneyAntiviral AgentsFibrosisMice, Inbred C57BLBoronic AcidsThreonine

Stichwörter der Autor:innen

Delanzomibfibrosiskidney

Substanzen

Proteasome InhibitorsAntiviral AgentsdelanzomibBoronic AcidsThreonine

Autor:innen und Institutionen

  • Department of Pharmacokinetics and Biopharmaceutics, Institute of Biomedical Sciences, Tokushima University.
  • Department of Renal and Cardiovascular Research, Otsuka Pharmaceutical Co., Ltd.

Zitieren

APA

Sawa-Aihara, A., Hattori, K., Nagao, G., Yamada, Y., & Ishida, T. (2023). Potential Efficacy of Proteasome Inhibitor, Delanzomib, for the Treatment of Renal Fibrosis. Biological and Pharmaceutical Bulletin. https://doi.org/10.1248/bpb.b22-00713

Vancouver

Sawa-Aihara A, Hattori K, Nagao G, Yamada Y, Ishida T. Potential Efficacy of Proteasome Inhibitor, Delanzomib, for the Treatment of Renal Fibrosis. Biological and Pharmaceutical Bulletin. 2023. doi:10.1248/bpb.b22-00713

BibTeX
@article{SawaAihara2023,
  author = {Sawa-Aihara, Ayano and Hattori, Katsuji and Nagao, Goshi and Yamada, Yoshihisa and Ishida, Tatsuhiro},
  title = {Potential Efficacy of Proteasome Inhibitor, Delanzomib, for the Treatment of Renal Fibrosis},
  journal = {Biological and Pharmaceutical Bulletin},
  year = {2023},
  doi = {10.1248/bpb.b22-00713}
}
Kostenlos starten →